Trial Outcomes & Findings for Venovenous CO2 Removal (VVCO2R) in Patients With COPD and Acute Respiratory Failure (NCT NCT00594009)
NCT ID: NCT00594009
Last Updated: 2019-03-12
Results Overview
The amount of CO2 removed in cc/min will be recorded. The level of blood flow (ml/min) and gas flow (l/min) at each measurement of CO2 removal will also be recorded
Recruitment status
TERMINATED
Study phase
NA
Target enrollment
1 participants
Primary outcome timeframe
0 to 96 hours
Results posted on
2019-03-12
Participant Flow
Participant milestones
| Measure |
Venovenous CO2 Removal (VVCO2R) in COPD
All patients enrolled in the trial will receive the proposed Patients who meet criteria will be placed on an extracorporeal device for CO2 removal for up to 96 hours for treatment of COPD exacerbation requiring hospitalization and intensive care
|
|---|---|
|
Overall Study
STARTED
|
1
|
|
Overall Study
COMPLETED
|
1
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Venovenous CO2 Removal (VVCO2R) in Patients With COPD and Acute Respiratory Failure
Baseline characteristics by cohort
| Measure |
VVCO2R in COPD
n=1 Participants
All patients enrolled in the trial will receive the proposed intervention
Rotaflow centrifugal pump (Maquet, Inc.): Patients who meet criteria will be placed on an extracorporeal device for CO2 removal for up to 96 hours for treatment of COPD exacerbation requiring hospitalization and intensive care
|
|---|---|
|
Age, Continuous
|
42 years
STANDARD_DEVIATION NA • n=5 Participants
|
|
Sex: Female, Male
Female
|
1 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
1 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
White
|
1 Participants
n=5 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
1 participants
n=5 Participants
|
|
chronic obstructive pulmonary disease (COPD) patients
|
1 Participants
n=5 Participants
|
PRIMARY outcome
Timeframe: 0 to 96 hoursThe amount of CO2 removed in cc/min will be recorded. The level of blood flow (ml/min) and gas flow (l/min) at each measurement of CO2 removal will also be recorded
Outcome measures
| Measure |
VVCO2R in COPD
n=1 Participants
All patients enrolled in the trial will receive the proposed intervention
Patients who meet criteria will be placed on an extracorporeal device for CO2 removal for up to 96 hours for treatment of COPD exacerbation requiring hospitalization and intensive care
|
|---|---|
|
The Amount of CO2 Transferred Through the Oxygenator at Various Levels of Blood and Gas Flow
|
75 cc/min
|
Adverse Events
VVCO2R in COPD
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Victor Cardenas, MD
University of Texas Medical Branch
Phone: (409) 772-2436
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place